Sum m ary :A battery of sixty-six blood samples from Senegal was analysed by the ParaSight F® test, the ICT Malaria PF® and the Malaria IgG CELISA®. These three assays detect the histidine rich protein 2 antigen of Plasmodium falciparum. Thick smear microscopy was used as the reference method. Sensitivity, specificity, predictive positive and negative values were respectively 89 %, 100 %, 100 %, 88 % for the ICT; 86 %, 93 %, 94 %, 85 % for the paraSight and 88 %, 87 %, 88 %, 87 % for the M alaria IgG CELISA. The three assays failed to detect two positive samples with P. ovale and P. malariae. Assays were also compared with regard to the expense of equipment and reagents and speed and ease of use. The rapid ICT and ParaSight F test can be performed with minimal training and may be specially useful in areas where P. falciparum is the predominant malaria species, in epidemic malaria regions, and where skilled microscopy is not readily available. M alaria remains the most important parasitic disease, causing about 2,000,000 deaths each year, mostly due to P la sm od iu m fa lc ip a r u m . The increase o f drug resistant strains and the increasing clinical importance o f malaria has led to efforts to improve diagnostic methods. M icroscopic examination o f blood smears remains the method o f choice for dia gnosing malaria in most settings, but effective micro scopy requires a quality m icroscope and extensive trai ning. Newer technologies that have been evaluated inclu de hybridization to DNA or RNA (A m broise Thomas, 1990; Franzen e t al., 1984), the polymerase chain reaction PCR (Barker e t al., 1992; Mc Lauglin e t al., 1987) and the QBC malaria assay (Levine, 1989). However Parasite, 1998, 5,[189][190][191][192] assays detecting the P la sm od iu m fa lc ip a r u m histidinerich protein 2 Pf HRP-2 (Howard et al., 1986), a watersoluble protein released from parasitized erythrocytes, are the current major commercial technologies. Related assays include the ParaSight F® test developed by Becton Dickinson, the ICT Malaria P.f.® developed by ICT Diagnostics (Sydney, Australia) and the Malaria IgG CELISA® developed by CelLabs (Sydney, Australia). Pf HRP-2 is identified using m onoclonal antibodies in different formats in these assays. The purpose of the pre sent study was to compare thick smears microscopy to these three companies assays which detect Pf HRP-2. MATERIALS A N D METHODSD u r i n g Novem ber 1996, sixty-six patients with malaria symptoms presenting at the Roi Bau doin out-patient clinic in Guediawaye, a su burb o f Dakar, Senegal were enrolled in the study. The age distribution was 1-65 years. Thirty-five were female and thirty-one w ere m ale; inform ed con sen t was 189 Note de rechercheArticle available at
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.